SEC Form 4 · accession 0001127602-17-027802
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred E Cohen
Director
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 10:07 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2017 | M | 54,250 | $4.27 | A | 173,660 | D | |
| Common StockF1 | Sep 18, 2017 | S | 54,250 | $5.42 | D | 119,410 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $4.27 | Sep 18, 2017 | M | 54,250 | D | Sep 21, 2012 | Sep 21, 2017 | Common Stock | 54,250 | 0 | D |
Explanation of responses
- F1The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.40 to $5.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- F2This transaction was made due to the upcoming expiration of the option.